The COVID-19 crisis shifted unprecedented resources to the diagnostics industry and presented a substantial growth opportunity for test manufacturers. A multitude of companies and entrepreneurs quickly pivoted toward developing innovative COVID tests, but whether they can survive post-pandemic exceptionalism remains to be seen.
Published in MedTech Strategist
Authors: Wendy Diller, Oded Ben-Joseph, Craig Steger, and Thomas Joyce
Abstract:
The COVID-19 crisis shifted unprecedented resources to the diagnostics industry and presented a substantial growth opportunity for test manufacturers. A multitude of companies and entrepreneurs quickly pivoted toward developing innovative COVID tests, but whether they can survive post-pandemic exceptionalism remains to be seen.
Outcome Capital Named Top Life Sceneces Investement Banking Firm 2025 by Life Science Review January 2025 Read the full article from Life Science Magazine here: Read More
Read MoreOutcome Capital Life Science Market Pulse December 2024 Click to view our LifeSciences Pulse Newsletter
DownloadWould you like to learn more about working with Outcome Capital or discuss your specific needs?